

**Table 3** Measurement values of variables

	Group	Baseline	T0	T1	T2	T3	T5	T7	T10
QT (ms)	Sugammadex	389 ± 30	390 ± 27	389 ± 29	388 ± 27	387 ± 28	386 ± 27	385 ± 28	380 ± 28
	Neostigmine	392 ± 26	390 ± 23	374 ± 25	375 ± 24	379 ± 24	390 ± 25	397 ± 27	398 ± 27
QTcB (ms)	Sugammadex	413 ± 24	414 ± 24	413 ± 23	414 ± 27	415 ± 27	413 ± 23	412 ± 24	415 ± 23
	Neostigmine	412 ± 20	414 ± 22	424 ± 19	414 ± 20	410 ± 23	406 ± 20	407 ± 25	409 ± 23
QTcF (ms)	Sugammadex	404 ± 21	404 ± 20	403 ± 21	404 ± 22	404 ± 21	402 ± 19	401 ± 20	400 ± 19
	Neostigmine	406 ± 18	406 ± 18	407 ± 16	402 ± 20	399 ± 19	399 ± 18	405 ± 20	404 ± 16
QTD (ms)	Sugammadex	36 ± 15	38 ± 16	36 ± 17	35 ± 20	33 ± 15	35 ± 15	36 ± 19	37 ± 20
	Neostigmine	38 ± 21	40 ± 24	38 ± 20	39 ± 22	42 ± 24	41 ± 23	43 ± 24	41 ± 25
QTcBD (ms)	Sugammadex	38 ± 15	40 ± 17	38 ± 18	40 ± 22	37 ± 15	40 ± 18	38 ± 19	38 ± 15
	Neostigmine	38 ± 24	42 ± 27	44 ± 24	44 ± 25	52 ± 33	39 ± 25	41 ± 25	39 ± 20
QTcFD (ms)	Sugammadex	39 ± 16	39 ± 17	38 ± 18	39 ± 21	38 ± 19	39 ± 19	41 ± 18	42 ± 19
	Neostigmine	38 ± 23	39 ± 24	42 ± 21	44 ± 25	48 ± 30	39 ± 25	43 ± 27	40 ± 23

Data are presented as mean ± standard deviation. *T0*: reversal of neuromuscular blockade, *T1–T10*: 1–10 min after reversal, *RR*: RR interval, *QT*: QT interval, *QTcB*: QT corrected using Bazett's formula, *QTcF*: QT corrected using Fredericia's formula, *QTD*: QT dispersion, *QTcBD*: QT dispersion corrected using Bazett's formula, *QTcFD*: QT dispersion corrected using Fredericia's formula